Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading 4.9% Higher – Still a Buy?

Shares of Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) traded up 4.9% during trading on Monday . The company traded as high as $0.45 and last traded at $0.44. 5,500 shares were traded during mid-day trading, an increase of 153% from the average session volume of 2,175 shares. The stock had previously closed at $0.42.

Sino Biopharmaceutical Stock Performance

The company has a quick ratio of 1.07, a current ratio of 1.15 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average price is $0.41 and its two-hundred day moving average price is $0.42.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.